Hemoglobin As A Predictor For COVID-19 Disease Severity

Nicholas Sarcia  
*University of New England College of Osteopathic Medicine, nsarcia@une.edu*

Dan Thai  
*University of New England College of Osteopathic Medicine, dthai@une.edu*

Andrea M. Bodine MD  
*Berkshire Medical Center, bodineandrea@gmail.com*

Follow this and additional works at: https://scholar.rochesterregional.org/advances

Part of the Emergency Medicine Commons, Infectious Disease Commons, and the Virus Diseases Commons

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

**Recommended Citation**


**ISSN: 2769-2779**

This Article is brought to you for free and open access by RocScholar. It has been accepted for inclusion in Advances in Clinical Medical Research and Healthcare Delivery by an authorized editor of RocScholar. For more information, please contact Advances@rochesterregional.org.
Hemoglobin As A Predictor For COVID-19 Disease Severity

Abstract
Background: The dilemma of who is at highest risk for COVID-19 severe disease and death persists. Hemoglobin levels may be an indicator of COVID-19 disease severity. There is inconsistent data on Emergency Department (ED) hemoglobin levels and severity of disease. Our objective was to examine if COVID-19 patients presenting with abnormal hemoglobin levels have an increased risk of severe disease and in-hospital mortality.

Methods: We conducted a retrospective cohort study at Berkshire Medical Center in Pittsfield, MA to investigate the relationship of COVID-19 disease severity with hemoglobin level. Inclusion criteria consisted of ED patients over 18 years with a COVID-19 diagnosis from July 1, 2021, to November 1, 2021. Exclusion criteria consisted of duplicate visits and patients without a hemoglobin value recorded. Patients with anemia were stratified by severity. Disposition categories from most to least severe were: ICU/PCU, medical floor, or discharge from ED. In-hospital mortality was recorded. Backward linear regression followed by z-tests were used for each abnormal hemoglobin category versus normal hemoglobin category.

Results: The four-month period included 341 ED visits coded for COVID-19. After excluding 113 visits, 228 were eligible for analysis. There were 132 discharged from the ED, 64 admitted to the medical floor, 32 to ICU/PCU, and 19 deaths. Backwards linear regression showed hemoglobin category was a significant predictor of hospital disposition (p < 0.0001) and mortality (p = 0.07). Z-test showed a significant difference in disposition for normal hemoglobin versus mild anemia (z = 2.1927, p = 0.03) and normal hemoglobin versus moderate/severe anemia (z = 3.6225, p = 0.0003). Z-test showed a significant difference in death for normal hemoglobin versus moderate/severe anemia (z = 3.2949, p = 0.001). Normal hemoglobin versus elevated hemoglobin had no significant difference for disposition (z = 0.356, p = 0.72) or death (z = 1.786, p = 0.07).

Discussion: Abnormal hemoglobin is associated with severity of disease and death COVID-19 patients. Increasingly severe anemia is more associated with severity of disease and death. Elevated hemoglobin is not associated with severity of disease or death.

Keywords
COVID-19, Hemoglobin, Anemia, Delta Variant

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Conflict of Interest Statement
We do not have conflicts of interest or financial disclosures.

Cover Page Footnote
Acknowledgements Special thanks to Paul Johansen MA, Biostatistician.

This article is available in Advances in Clinical Medical Research and Healthcare Delivery:
https://scholar.rochesterregional.org/advances/vol2/iss2/3
ARTICLE

Hemoglobin as a Predictor for COVID-19 Disease Severity

Nicholas Sarcia a,*, Dan Thai a, Andrea M. Bodine b

a University of New England College of Osteopathic Medicine, UK
b Berkshire Medical Center, UK

Abstract

Background: The dilemma of who is at highest risk for COVID-19 severe disease and death persists. Hemoglobin levels may be an indicator of COVID-19 disease severity. There is inconsistent data on Emergency Department (ED) hemoglobin levels and severity of disease. Our objective was to examine if COVID-19 patients presenting with abnormal hemoglobin levels have an increased risk of severe disease and in-hospital mortality.

Methods: We conducted a retrospective cohort study at Berkshire Medical Center in Pittsfield, MA to investigate the relationship of COVID-19 disease severity with hemoglobin level. Inclusion criteria consisted of ED patients over 18 years with a COVID-19 diagnosis from July 1, 2021, to November 1, 2021. Exclusion criteria consisted of duplicate visits and patients without a hemoglobin value recorded. Patients with anemia were stratified by severity. Disposition categories from most to least severe were: ICU/PCU, medical floor, or discharge from ED. In-hospital mortality was recorded. Backward linear regression followed by z-tests were used for each abnormal hemoglobin category versus normal hemoglobin category.

Results: The four-month period included 341 ED visits coded for COVID-19. After excluding 113 visits, 228 were eligible for analysis. There were 132 discharged from the ED, 64 admitted to the medical floor, 32 to ICU/PCU, and 19 deaths. Backwards linear regression showed hemoglobin category was a significant predictor of hospital disposition (p < 0.0001) and mortality (p = 0.07). Z-test showed a significant difference in disposition for normal hemoglobin versus mild anemia (z = 2.1927, p = 0.03) and normal hemoglobin versus moderate/severe anemia (z = 3.6225, p = 0.0003). Z-test showed a significant difference in death for normal hemoglobin versus moderate/severe anemia (z = 3.2949, p = 0.001). Normal hemoglobin versus elevated hemoglobin had no significant difference for disposition (z = 0.356, p = 0.72) or death (z = 1.786, p = 0.07).

Discussion: Abnormal hemoglobin is associated with severity of disease and death COVID-19 patients. Increasingly severe anemia is more associated with severity of disease and death. Elevated hemoglobin is not associated with severity of disease or death.

Keywords: COVID-19, Hemoglobin, Anemia, Delta variant

1. Introduction

The dilemma of who is at highest risk for COVID-19 severe disease and death persists. In July 2021, the Delta variant became the dominant strain in the United States causing more severe disease and vaccine breakthrough. Through October 2021, there had been over 233 million cases and 4.8 million deaths worldwide. Multiple comorbid conditions and risk factors have been linked to more severe disease such as increased age, hypertension, cardiovascular disease, diabetes, obesity, and chronic lung disease. Worse outcomes have been associated with abnormal laboratory values of liver enzymes, kidney function, and inflammatory markers. COVID-19 association with comorbidities and laboratory values may present in a similar fashion to other acute and chronic respiratory conditions. Patients with severe acute respiratory diseases, such as community-acquired
pneumonia have an increased risk of mortality if anemia is present. Anemia was classified according to the World Health Organization (WHO) definition (Table 1), as hemoglobin (Hb) levels <13.0 g/dL in males and <12.0 g/dL in females. Severity of anemia was defined in males by: mild 11–12.9 g/dL, moderate 8–10.9 g/dL, and severe <8 g/dL. Severity of anemia was defined in females by: mild 11–11.9 g/dL, moderate 8–10.9 g/dL, severe <8 g/dL. Elevated hemoglobin in males and females was defined as ≥16 g/dL. These categories comprised the abnormal hemoglobin groups. Severity of disease was measured by hospital disposition with the most severe to mild as ICU/PCU (intensive care unit/progressive care unit), medical floor, or ED discharge. In-hospital mortality was defined as patients who died before discharge. ICU admission was made based upon the clinical judgment of the ICU attending physician and ED provider. Patients who required intubation and ventilation or had refractory hypoxia were generally admitted to the ICU. When no beds were available in the ICU, patients were admitted to the PCU, which is an intermediate level of care between the medical floor and ICU at BMC.

Data was obtained from BMC Medical Records Department using ICD-10 codes for COVID-19 and patients who presented initially through the ED. Electronic medical records were reviewed for hemoglobin on initial CBC, in-hospital mortality, and disposition to ICU/PCU, medical floor, or ED discharge. Demographics of age at initial presentation, sex, race, and vaccination status were also recorded independently. Patients with anemia were then stratified by severity. Backward linear regression was used for analysis followed by z-tests to compare each abnormal hemoglobin category to the normal hemoglobin category. All data was de-identified.

2. Methods

We conducted a retrospective cohort study at Berkshire Medical Center (BMC) in Pittsfield, MA to investigate the relationship of COVID-19 disease severity and in-hospital mortality with hemoglobin (Hgb) levels. IRB exemption was obtained.

Inclusion criteria consisted of patients 18 years and older presenting to the ED with a diagnosis of COVID-19 from July 1, 2021, to November 1, 2021. Records were reviewed for demographics of age, sex, race, and vaccination status which was positive if documented on ED record. Exclusion criteria consisted of duplicate visits and patients who did not have a recorded hemoglobin value. Duplicate visits greater than or equal to 48 days were considered a new infection and counted as an additional subject. Visits less than 48 days were subjected to selection of the most severe presentation requiring the highest level of care and exclusion of the other visit(s) in the following order: in-hospital death, highest level of care, lowest abnormal hemoglobin value, highest abnormal hemoglobin value, all other things being equal, choose the earliest visit.

Anemia was classified according to the World Health Organization (WHO) definition (Table 1), as hemoglobin (Hb) levels <13.0 g/dL in males and <12.0 g/dL in females. Severity of anemia was defined in males by: mild 11–12.9 g/dL, moderate 8–10.9 g/dL, and severe <8 g/dL. Severity of anemia was defined in females by: mild 11–11.9 g/dL, moderate 8–10.9 g/dL, severe <8 g/dL. Elevated hemoglobin in males and females was defined as ≥16 g/dL. These categories comprised the abnormal hemoglobin groups. Severity of disease was measured by hospital disposition with the most severe to mild as ICU/PCU (intensive care unit/progressive care unit), medical floor, or ED discharge. In-hospital mortality was defined as patients who died before discharge. ICU admission was made based upon the clinical judgment of the ICU attending physician and ED provider. Patients who required intubation and ventilation or had refractory hypoxia were generally admitted to the ICU. When no beds were available in the ICU, patients were admitted to the PCU, which is an intermediate level of care between the medical floor and ICU at BMC.

Data was obtained from BMC Medical Records Department using ICD-10 codes for COVID-19 and patients who presented initially through the ED. Electronic medical records were reviewed for hemoglobin on initial CBC, in-hospital mortality, and disposition to ICU/PCU, medical floor, or ED discharge. Demographics of age at initial presentation, sex, race, and vaccination status were also recorded independently. Patients with anemia were then stratified by severity. Backward linear regression was used for analysis followed by z-tests to compare each abnormal hemoglobin category to the normal hemoglobin category. All data was de-identified.

Table 1. Hemoglobin categories.

<table>
<thead>
<tr>
<th></th>
<th>Severe</th>
<th>Moderate</th>
<th>Mild</th>
<th>Normal</th>
<th>Elevated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>&lt;8 g/dL</td>
<td>8–10.9 g/dL</td>
<td>11–12.9 g/dL</td>
<td>13–15.9 g/dL</td>
<td>≥16 g/dL</td>
</tr>
<tr>
<td>Female</td>
<td>&lt;8 g/dL</td>
<td>8–10.9 g/dL</td>
<td>11–11.9 g/dL</td>
<td>12–15.9 g/dL</td>
<td>≥16 g/dL</td>
</tr>
</tbody>
</table>
3. Results

During the four-month period there were 341 ED visits coded for COVID-19 in patients 18 and older. After excluding 70 subjects who did not have a hemoglobin value and 45 repeat visits with two subjects in both exclusion criteria, there were a total of 228 subjects for analysis. One patient had a repeat visit greater than 48 days which was counted as a separate visit. There were a total of 132 discharged from the ED, 64 admitted to the medical floor, and 32 to the ICU/PCU. Of the 228 subjects, 19 died during their hospital stay (Fig. 1).

Ages ranged from 18 to 97 with an average age of 56. Average age in normal Hgb was 53, mild 62, moderate 73, severe 78, and elevated 54. Males were 46% of the subjects. Males for each hemoglobin category consisted of 64% normal Hgb, 39% mild, 58% moderate, 29% severe, and 50% elevated. Of the subjects 53% were vaccinated. Vaccination status for each hemoglobin category consisted of 48% normal Hgb, 71% mild, 75% moderate, 50% severe, and 39% elevated (Table 2).

Hemoglobin levels ranged from 7.9 to 18.6. There were a total of 154 normal Hgb, 36 mild, 17 moderate, 2 severe, and 19 elevated (Table 3). Distribution of each hemoglobin category for disposition (\(\times\)) and death (\(\bullet\)) are shown. Due to the small number of subjects in the severe anemia group, the moderate and severe categories were combined for analysis.

Five variables were used in backwards linear regression to predict disposition: Age, Vaccination status, Sex, Race, and Hemoglobin category. Of these five variables, two remained significant at the alpha = 0.10 level: Hemoglobin category (\(p < 0.0001\)) and Age (\(p = 0.002\)). Z-test compared normal

![Fig. 1. Study population.](image)

<table>
<thead>
<tr>
<th>Table 2. Demographics for hemoglobin categories.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>Age (mean)</td>
</tr>
<tr>
<td>Males (%)</td>
</tr>
<tr>
<td>Race (white %)</td>
</tr>
<tr>
<td>Vaccinated (%)</td>
</tr>
</tbody>
</table>
hemoglobin versus mild anemia, moderate/severe anemia, and elevated hemoglobin for disposition with a significance level of \( p \leq 0.05 \). There was significant difference in disposition for normal hemoglobin versus mild anemia (\( z = 2.1927, p = 0.03 \)) and normal hemoglobin versus moderate/severe anemia (\( z = 3.6225, p = 0.0003 \)). There was no significant difference in disposition for normal hemoglobin versus elevated hemoglobin (\( z = 0.356, p = 0.72 \)).

Five variables were used in backwards linear regression to predict death: Age, Vaccination status, Sex, Race, and Hemoglobin category. Of these five variables, three remained significant at the alpha = 0.10 level: Patient Age (\( p < 0.0001 \)), Vaccination status (\( p = 0.022 \)), and Hemoglobin category (\( p = 0.07 \)). Z-test compared normal hemoglobin versus mild anemia. Moderate/severe anemia, and elevated hemoglobin for death with significance level at \( p \leq 0.05 \). There was a significant difference in death for normal hemoglobin versus moderate/severe anemia (\( z = 3.2949, p = 0.001 \)). There was no significant difference in death for normal hemoglobin versus mild anemia (\( z \)-score = 0.7259, \( p = 0.47 \)) or normal hemoglobin versus elevated hemoglobin (\( z = 1.786, p = 0.07 \)).

### 4. Discussion

We found COVID-19 patients who presented to the ED with an abnormal hemoglobin had a significant association with severity of disease measured by disposition, and death by in-hospital mortality. For disposition, there was increasing significance with severity of anemia, particularly at the moderate-severe levels and no significance with elevated hemoglobin. For death, there was significance with moderate/severe anemia and no significance with mild anemia or elevated hemoglobin. We satisfied our hypothesis that COVID-19 patients with abnormal hemoglobin had more severe disease only with the anemic groups and for in-hospital mortality only with moderate/severe anemia. We were unable to satisfy our hypothesis for severity of disease in the elevated hemoglobin group and in-hospital mortality in mild anemia and elevated hemoglobin groups.

Our findings of abnormal hemoglobin predicting more severe disease and death are partially consistent with other studies that have shown a significant association in either severity of disease or death, but not both.\(^6,7\) Our data is inconsistent with other studies that have shown no association of anemia and severe illness or death,\(^8,9\) and an association of death with elevated hemoglobin which we found to be non-significant.\(^10\) These inconsistencies may be related to our limitations which include a lack of subject racial diversity thereby decreasing the generalizability of the study, and a small sample size, especially in the severe anemia category which was combined with moderate anemia for analysis. We were unable to determine if patients who were discharged to another facility or home later died from disease. It may be useful to record death out of the hospital within a certain time frame. This study also has several confounding variables such as chronic diseases or other abnormal laboratory values that may have placed certain patients at higher risk. Patients with chronic disease may have had a chronic abnormal hemoglobin or have multiple diseases that would subject them to placement at a higher level of care such as the ICU/PCU or death. These confounding factors can only be controlled for by a more extensive study design and analysis. The disposition of the patient is also dependent on the provider which adds subjectivity to the analysis of severity of disease.

Future studies that have a larger and diverse sample size controlling for confounding variables would be able to give a more precise interpretation on severity of disease and death. Follow-up of patients after discharge may provide a better representation of the actual mortality rate. It also may be useful to analyze data from different time periods to compare with the delta variant, which was the dominant source of infection in this study, versus other strains.

The strengths of our study include addition of the elevated hemoglobin category which fewer studies have assessed, and the study population which was concentrated during the delta variant outbreak. The data from our study provides clinical relevance as it suggests patients with abnormal hemoglobin to be at higher risk for severe disease and death which can be considered in assessing risk for COVID-19 disease in the ED. We can also emphasize the importance of vaccination and additionally the risk of death in the older population as it was a more significant predictor of death than the hemoglobin category in our analysis.

### Table 3. Hgb Category for disposition and death.

<table>
<thead>
<tr>
<th>Category</th>
<th>Normal</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Elevated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discharge</td>
<td>99</td>
<td>16</td>
<td>4</td>
<td>0</td>
<td>13</td>
</tr>
<tr>
<td>Floor</td>
<td>42</td>
<td>13</td>
<td>4</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>ICU/PCU</td>
<td>13</td>
<td>7</td>
<td>9</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Death</td>
<td>8</td>
<td>3</td>
<td>5</td>
<td>0</td>
<td>3</td>
</tr>
</tbody>
</table>

Number of patients in each disposition and deaths.
5. Conclusion

Within the limitations of the study, abnormal hemoglobin appears to be associated with severity of disease and death COVID-19 patients. Increasingly severe anemia is more associated with severity of disease and death. Elevated hemoglobin is not associated with severity of disease or death.

Conflict of interest

We do not have conflicts of interest or financial disclosures.

Author contribution

Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing — original draft, Writing — review & editing

References